Retinal ischemia-reperfusion (IR) injury is a major cause of irreversible vision loss due to the selective vulnerability of retinal ganglion cells (RGCs) to metabolic stress. These neurons, which transmit visual information from the retina to the brain, are particularly sensitive to oxidative damage, inflammation, and apoptotic signaling triggered during reperfusion. This study evaluates the ability of bortezomib, a proteasome inhibitor, to preserve RGC integrity and function in a rat model of experimental IR injury, focusing on structural survival, functional recovery, and molecular mechanisms underlying neuroprotection.
Male Sprague-Dawley rats were randomly assigned to four groups: sham-operated control, saline-treated, low-dose bortezomib (0.05 mg/kg), and high-dose bortezomib (0.2 mg/kg). Bortezomib or vehicle was administered intraperitoneally 30 minutes before inducing retinal ischemia via elevated intraocular pressure (130 mmHg for 45 minutes). Animals were sacrificed at 7 days post-injury for assessment of RGC density and retinal function. The eyes were enucleated, and retinas were flat-mounted for immunofluorescence staining using NeuN, a marker specific for mature neuronal nuclei.
NeuN immunostaining revealed a significant reduction in RGC density in the saline-treated group compared to controls, with a marked thinning of the ganglion cell layer. In the low-dose bortezomib group, RGC loss was partially attenuated but still evident. However, in the high-dose bortezomib group, RGC density remained comparable to that of the control group, indicating near-complete preservation of these critical neurons. Quantitative analysis confirmed a statistically significant difference between the saline and high-dose bortezomib groups (p < 0.5,6-Dibromo-1H-indole-3-carbaldehyde Technical Information 05), highlighting the dose-dependent nature of protection.
Electroretinography (ERG) was performed at 7 days post-injury to assess functional outcomes. The b-wave amplitude, which reflects inner retinal activity including RGC function, was significantly reduced in the saline group. Pretreatment with bortezomib, especially at high dose, resulted in a substantial recovery of the b-wave response. The relative b-wave ratio in the high-dose group was significantly higher than in both the saline and low-dose groups (p < 0.05), demonstrating improved electrophysiological function despite ischemic insult. To understand the underlying mechanisms, molecular analyses were conducted. Western blotting showed increased expression of pro-apoptotic proteins p53 and Bax in the saline group, consistent with activation of intrinsic apoptosis pathways. In contrast, bortezomib pretreatment led to a significant downregulation of both p53 and Bax, particularly in the high-dose group. This suggests that bortezomib interrupts the apoptotic cascade by modulating key regulators of cell death.Ataluren CFTR
Immunofluorescence for TUNEL staining confirmed widespread DNA fragmentation in the inner retina of saline-treated animals.PMID:34670413 In contrast, the number of TUNEL-positive cells was dramatically reduced in the bortezomib-pretreated groups, with minimal labeling observed in the high-dose cohort. This provides direct evidence of reduced apoptosis in RGCs following bortezomib administration.
Further investigation into inflammatory and oxidative stress pathways revealed that bortezomib suppressed NF-κB activation. Nuclear translocation of NF-κB p65 was prominent in the saline group but markedly diminished in the high-dose bortezomib group. This inhibition correlated with reduced expression of iNOS, ICAM-1, MCP-1, and TNF-α, all known mediators of neuroinflammation and vascular dysfunction.
Oxidative markers such as nitrotyrosine and 8-OHdG were also significantly elevated in the saline group. Their expression was substantially lower in bortezomib-treated animals, indicating a reduction in oxidative damage. This effect may be secondary to decreased inflammatory burden and enhanced cellular resilience.
Proteasome activity assays confirmed effective inhibition of chymotrypsin-like activity in retinal tissue after bortezomib administration. No significant difference was found between low- and high-dose groups, suggesting that maximal target engagement was achieved even at the lower dose.
In summary, bortezomib demonstrates robust neuroprotective effects in retinal IR injury by preserving RGC structure and function. It achieves this through multiple interconnected mechanisms: inhibition of NF-κB-driven inflammation, suppression of oxidative stress, and blockade of apoptotic pathways involving p53 and Bax. The high-dose regimen provided the most consistent and significant protection, maintaining RGC density and ERG responses close to normal levels.
These findings underscore the potential of bortezomib as a therapeutic agent for conditions involving RGC degeneration, such as glaucoma and ischemic optic neuropathy. While systemic administration poses challenges for clinical translation, future research should explore localized delivery methods—such as intravitreal injection or sustained-release formulations—to maximize efficacy while minimizing off-target effects. The results provide strong preclinical support for further development of proteasome inhibitors in neuroprotective ophthalmology.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com